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Previous reports in the literature suggest that
lower extremity revascularization is cost-effective for
the treatment of chronic lower extremity ischemia in
comparison with primary amputation.1,2 These stud-
ies indicate that although the initial cost of bypass
grafting may be higher than that of amputation, the
additional expense of postamputation rehabilitation,
prosthesis construction, and support services negates
the initial cost benefit of primary amputation.
Most previous studies, however, fail to account for
the resources used in bypass graft maintenance, even
though optimal graft patency and limb salvage depend
on an active surveillance program.3,4 Originally popu-
larized by Bandyk et al,5 lower extremity surveillance
programs rely on interval duplex examination of the
graft and eventuate in repair of identified stenoses in
up to one third of all lower extremity autogenous
bypass grafts.6 Despite this relatively high rate of sur-
gical revision, however, graft patency and limb salvage
rates have improved by only 10% to 15%.4 We have
become increasingly concerned about the high fre-
quency with which such revisions are required, the
cost of which has been neither analyzed nor justified.
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Objective: Infrainguinal graft surveillance leads to intervention on the basis of duplex-iden-
tified stenoses. We have become increasingly concerned about the high frequency with
which such revisions are required to maximize graft patency and limb salvage rates. The
economic implications of these procedures have not been carefully analyzed or justified.
Methods: We retrospectively reviewed 155 consecutive autogenous infrainguinal bypass
grafts performed for chronic leg ischemia in 141 patients. All patients were enrolled in
a prospective surveillance program using color flow duplex imaging. Full economic
appraisal (cost analysis, cost-effect analysis, and cost-benefit analysis) was performed for
all graft surveillance and limb salvage–related interventions through use of standard
accounting and valuation techniques.
Results: Mean follow-up was 27 months. Five-year assisted primary patency (72%) and
limb salvage rates (91%) were calculated by means of life table analysis. A total of 61
grafts required 86 revisions. Within 1 year of implantation, 36% of the grafts required
revision. During this first year, the mean cost per graft enrolled was $9417. Time inter-
vals after the initial year demonstrated a reduced annual revision rate (6%) and cost
($1725 per graft). The mean 5-year cost of graft maintenance ($16,318) approached
that of the initial bypass graft ($19,331). The sum of the initial cost of bypass graft and
5-year graft maintenance cost ($35,649) was similar to the cost of amputation
($36,273). Grafts revised for duplex-detected stenoses (n = 46), in comparison with
those revised after thrombosis (n = 15), had an improved 1-year patency (93% vs 57%;
P < .01), required fewer amputations (2% vs 33%; P < .01), less frequently required mul-
tiple graft revisions (P = .06), and generated fewer expenses (at 12 months after revi-
sion, $17,688 vs $45,252, P < .01).
Conclusion: The cost associated with graft maintenance is significant, particularly with-
in the first year, and demands consideration. Revision of a duplex-identified stenosis was
significantly less costly than revision after graft thrombosis. Compared with the cost of
limb amputation, limb salvage–related expenses appear to be justified. (J Vasc Surg
2000;32:1-12.)
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CLINICAL RESEARCH STUDIES
From the Western Vascular Society
We therefore set out to perform a detailed eco-
nomic evaluation of the 141 cases most recently
enrolled in our prospective infrainguinal graft sur-
veillance program. (1) We began by performing a
detailed cost analysis for the primary bypass proce-
dure, the graft surveillance program, and alternative
therapies (major amputation). (2) Through use of
the derived cost data, a cost-effect analysis was car-
ried out for the surveillance interval on the basis of
the cost/limb salvage ratio. (3) Finally, a cost-bene-
fit analysis was performed by comparison of
cost/limb salvage ratios of the contemporary cohort
with those of a historical group in which revision was
performed only for symptoms of recurrent leg
ischemia.
METHODS
Patient cohort. We retrospectively reviewed the
surveillance data of the 155 most recent autogenous
infrainguinal bypass procedures performed for
chronic leg ischemia. All patients were considered
for arterial reconstruction if maintenance of a viable
limb would confer a mobility advantage (ability to
transfer or independently ambulate). Indications for
operation and patient demographics are listed in
Table I.
Our preferred conduit was autogenous greater
saphenous vein constructed through use of the
reversed (70%) or in situ technique (19%). When the
greater saphenous vein was unavailable, our choice
was the lesser saphenous, cephalic, or basilic vein,
either alone or as a spliced composite autogenous
graft (10.5%). Patients in whom prosthetic material
was used were excluded because previous reports
had failed to demonstrate a significant benefit for
surveillance of prosthetic grafts.4 More than 90% of
distal anastomoses were constructed to infragenicu-
late vessels (Table II).
Postoperative evaluations were scheduled at 6
weeks, 3 months, 6 months, 9 months, and 12
months and then at 6-month intervals. Follow-up
consisted of a focused history and physical examina-
tion, Doppler-derived ankle/brachial index determi-
nation, and color-flow duplex scanning of the entire
bypass conduit, inflow, and outflow arteries. Specific
criteria for graft revision were based on an extensive
review of the literature and previous experience
(Table III). These criteria were previously validated
through prospective application.7
Surgical results. Mean follow-up after revascu-
larization was 27.3 ± 22.7 months (range, 4-110
months). The prospective application of our inten-
sive surveillance protocol yielded a 5-year assisted
primary patency of 72.3%, a secondary patency of
79.4%, and a limb salvage rate of 91.4% (Fig 1). A
mean of 5.2 ± 3.3 graft surveillance evaluations per
patient was performed. Because most graft stenoses
develop within the first year of implantation, this
interval was surveyed with the highest intensity.
A total of 86 revisions were performed on 61
of the 155 bypass grafts. Ninety-four grafts (61%)
underwent no revision; 42 grafts (27%) underwent
1 revision; and 19 grafts (12%) underwent multiple
revisions. Forty-six grafts were revised for duplex-iden-
tified stenoses, and 15 grafts were revised after throm-
bosis.
Of the 46 grafts revised electively for duplex-identi-
fied stenoses, 84% underwent preoperative angiography
to confirm the location and severity of the stenosis and
exclude a synchronous lesion. Procedures performed
included percutaneous angioplasty (8% of revisions),
patch angioplasty (18% of revisions), and graft interpo-
sition/translocation (73% of revisions). Secondary revi-
sions were required in 12 (26%) of the 46 grafts because
of the development of metachronous stenoses.
Subsequent failure occurred in five (11%) of the grafts
(mean time from revision to thrombosis, 4.9 months),
and one limb (2%) required major amputation.
Fifteen grafts required revision after thrombosis.
Six patients developed early postoperative graft throm-
bosis and were returned directly to the operating room
for catheter thrombectomy and revision. The remain-
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Table I. Patient demographics and operative indi-
cations
Mean age (y) 69.1 ± 9.8
Female gender (%) 43
Tobacco use (%) 43
Diabetes (%) 39
Hypertension (%) 65
End-stage renal disease (%) 4.5
Tissue loss (%) 45
Rest pain (%) 34
Claudication (%) 19
Popliteal aneurysm (%) 1.3
Table II. Distribution of inflow and outflow vessels
Percent
Graft origin
Common femoral artery 56
Superficial femoral artery 24
Profunda femoris artery 8
Popliteal artery 11
Graft insertion
Above knee popliteal 7
Below knee popliteal 36
Tibial/pedal 56
der presented with late graft thrombosis and under-
went catheter-directed thrombolysis before surgical
revision. Patients in whom hemodynamically signifi-
cant lesions could not be identified were treated with
chronic anticoagulation (these expenses were not
included in the cost analysis). Multiple revisions were
required in seven (47%) of the 15 grafts. Subsequent
thrombosis occurred in eight (53%) of the grafts
(mean time from revision to thrombosis, 2.5 months).
Five limbs (33%) required major amputation.
Statistics. Calculation of primary, primary assist-
ed, and secondary graft patency and limb salvage rates
was carried out by means of life table analysis accord-
ing to the revised recommended standards of the
Joint Council of the Society for Vascular Surgery and
the North American Chapter of the International
Society for Cardiovascular Surgery.8 All cost data are
presented as means ± SDs, and statistical significance
was determined by application of an unpaired Student
t test. Comparability of major risk factors among
patient cohorts was performed by means of χ2 analy-
sis. All data are reported with regard to a level of sig-
nificance of a P value less than .05.
Cost analysis. The simplest form of economic
evaluation considers only the costs associated with a
program and is therefore an incomplete form of eco-
nomic appraisal. In consideration of costs, it should
be remembered that the objective in valuing costs is
to obtain an estimate of the worth of the resources
depleted by the program. For this evaluation, hospi-
tal cost was calculated from the standpoint of the
health care provider through use of a standard unit-
cost system for each procedure charge unit. This sys-
tem is fully loaded (ie, the system includes both
direct and indirect costs) and is updated annually by
the Finance Department of the University Medical
Center of the Arizona Health Science Center.
Hospital costs were adjusted according to the annu-
al Consumer Price Index (CPI)* and are reported in
terms of the value of the 1998 dollar. Physician
expense data were derived from Medicare procedur-
al reimbursement figures according to the Resource-
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Table III. Stratification of risk of graft thrombosis by surveillance data
Category* High velocity criteria Low velocity criteria ∆ ABI
I (highest risk) PSV > 300 cm/s or Vr > 3.5 and GFV < 45 cm/s or > 0.15
II (high risk) PSV > 300 cm/s or Vr > 3.5 and GFV > 45 cm/s and < 0.15
III (intermediate risk) 180 < PSV > 300 cm/s or Vr > 2.0 and GFV > 45 cm/s and < 0.15
IV (low risk) PSV < 180 cm/s and Vr < 2.0 and GFV > 45 cm/s and < 0.15
PSV, Duplex-derived peak systolic velocity at site of flow disturbance; GFV, graft flow velocity (global or distal); Vr, velocity ratio of
stenosis to more proximal graft segment of same caliber; ABI, Doppler-derived ankle-brachial index.
*Category I: patients are hospitalized and anticoagulated; lesions are repaired promptly. Category II: lesions are repaired electively (with-
in 2 weeks). Category III: lesions are closely observed with serial duplex examination and are repaired only if they progress. Category
IV: lesions are at low risk (we have observed few failures in this group).
*As reported for the Western Region by the US Department of
Labor, Bureau of Labor Statistics. The annual values used in the
study were as follows: 1990, 78.4; 1991, 83.4; 1992, 85.2; 1993,
87.9; 1994, 90.8; 1995, 93.2; 1996, 95.3; 1997, 97.9.
Fig 1. Cumulative limb salvage and graft patency rates of 155 consecutive bypass grafts performed for
chronic lower extremity ischemia.
Based Relative Value Scale for the 1997-1998 fiscal
year. Allowance for differential timing of costs was
performed through use of an annualized future dis-
count rate of 5% per year.
The mean cost of each surveillance visit was
based on fixed and overhead vascular laboratory
operating expenses for the 1997-1998 fiscal year and
yielded an estimated cost of $112 per examination
(see Appendix 1). This is in close agreement with
previous vascular laboratory cost analysis data9 and
the 1998 Medicare reimbursement (CPT [Current
Procedural Terminology] code 93926, charge $172,
reimbursement $120.25).
A comprehensive review of all limb-salvage relat-
ed procedures performed at our institution generat-
ed the following cost data:
For each patient, all graft-related surveillance
studies, angiographic studies, interventions, and
postdischarge rehabilitation costs were recorded for
the following intervals after the bypass graft proce-
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Table IV. Estimated cumulative cost of each graft enrolled in an intensive surveillance program
Cumulative Mean no. of Cumulative Mean no. of
Mean no. probability revisions per probability of revisions per Cumulative Mean cost
Interval of follow-up of revision graft revised revision for graft revised probability of per patient
(mo) evaluations for stenosis (stenosis) thrombosis (thrombosis) amputation ($)
3 1.4 .088 1.17 .055 1.2 .02 3,764
6 2.7 .164 1.19 .074 1.41 .034 4,896
12 3.7 .255 1.29 .11 1.40 .048 9,417
24 5.2 .340 1.35 .132 1.43 .068 12,861
36 6.5 .391 1.37 .135 1.43 .086 14,693
48 7.5 .402 1.43 .146 1.41 .086 15,259
60 8.3 .428 1.40 .168 1.41 .086 16,318
Fig 2. Cumulative probability for graft revision of duplex-identified graft stenoses (n = 46) and for graft
revision after thrombosis (n = 15).
Table V. Cost effect of patient subgroups
Patency (%) Limb salvage Mean cost per
1 year (%) 1 year patient 1 
No. of after after year after
patients revision (± SE) revision (± SE) implantation ($)
Grafts without stenosis or thrombosis 94 92.8 (patency after implantation) 96.9 1,202
Grafts requiring revision for stenosis 46 93.1 97.8 17,688
Grafts requiring revision for thrombosis 15 56.8 66.0 45,252
dure: 0 to 3 months, 4 to 6 months, 7 to 12 months,
13 to 24 months, 25 to 36 months, 37 to 48
months, and 49 to 60 months. Thirty-six percent of
the grafts required revision within 1 year of implan-
tation (11% after thrombosis, 25% for duplex-identi-
fied stenosis). Later intervals were characterized by a
significantly lower (6%) annual rate of revision (Fig
2). Analysis of these procedural cost data and the
cumulative revision rate curves for stenosis and
thrombosis allow one to predict the average cost of
lower extremity graft surveillance and maintenance
on an individual basis. Because the number of scans
performed and the probability of revision vary as a
function of time from bypass grafting, it is necessary
to express cost as a function of time from bypass
grafting. Table IV presents the predicted postimplan-
tation cost for a patient enrolled in an intensive sur-
veillance program over specific time intervals. These
data consider all limb salvage–related costs and
include noninvasive examination, all diagnostic pro-
cedures, all graft interventions, amputation (when
required), and postdischarge rehabilitation (when
necessary). Obviously, individual grafts that devel-
oped early flow abnormalities or required multiple
attempts to reestablish flow after thrombosis were
more costly than grafts without such abnormalities.
With these previously unanalyzed costs docu-
mented, an equitable cost analysis of primary ampu-
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Fig 3. Cumulative patency for grafts revised after duplex identified stenoses (n = 46) and for grafts revised
after thrombosis (n = 15).
Mean cost of primary bypass procedure (including preoperative angiogram): $19,331 ± 5,300 (range, $11,321-$32,169)
Mean cost of a surveillance follow-up visit (including a duplex scan): $112 (see Appendix 1)
Mean cost for elective revision of a duplex-identified stenosis (including preoperative angiography, when performed):
Surgical revision: $13,003 ± 5,935 (range, $8,625-$39,835)
Percutaneous transluminal angioplasty: $3,623 ± 445 (range, $2,955-$4,685)
Weighted average cost: $11,779
Mean cost for revision after thrombosis:
Thrombectomy/revision: $18,519 ± 8,267 (range, $9,215-$36,090)
Thrombolysis/revision: $22,532 ± 4,750 (range, $14,032-$28,275)
Weighted average cost: $21,997
Mean cost for major amputation, prosthesis, and rehabilitation:
Inpatient: $15,801
Prosthesis (temporary and/or permanent): $6,840
Inpatient/outpatient rehabilitation: $13,632
$36,273 ± 9,336 (range: $25,318-$49,879)
tation and limb salvage is now possible. The costs of
the primary limb salvage procedure ($19,331) and 5
years of graft maintenance ($16,318) yield a com-
bined 5-year limb salvage cost of $35,649. This fig-
ure is more similar to the cost of amputation
($36,273) than previously predicted, and a pure cost
analysis of primary amputation versus limb salvage
demonstrates equivalency.
Cost-effect analysis. Next, we must address
whether the surveillance program positively
impacted limb salvage to a sufficient degree to jus-
tify the additional expenses as an efficient utiliza-
tion of our medical resources. This prompts the
need for a cost-effect analysis. In this form of eco-
nomic evaluation, the consequences of the pro-
gram cost are measured in appropriate units. In the
case of a duplex surveillance program, the direct
benefits of the program are defined as a quantita-
tive measure of limb salvage. Although surgical
results vary somewhat, most would agree that graft
surveillance has improved the 5-year limb salvage
rate by approximately 15%. That is, a surveillance
program applied to 100 limbs would save approx-
imately 15 limbs over 5 years and generate a cost
of $1,631,800. Thus, the cost per limb saved by
the surveillance program is calculated to be
$108,786. Although at first glance this expense
appears to be prohibitive, one must also recognize
the potential indirect benefits of such a program.
Specifically, with the identification and treatment
of grafts at risk for thrombosis, costly thrombolysis
procedures and amputations may be avoided and
significant cost savings may thus be realized.
The need to consider these costs can more clearly
be demonstrated if we examine the cost effect within
subgroups of our patient cohort. Independent cumu-
lative patency rates were calculated from the time of
revision to predict the utility of graft revision for a
duplex-identified stenosis versus the utility of revision
after thrombosis (Fig 3). The grafts revised for
duplex-identified stenoses fared far better than the
grafts revised after thrombosis (for graft patency at 12
months after revision, 93.1% vs 56.8%). Moreover,
33% of limbs revised after thrombosis eventually
required amputation. In contrast, only 2% of limbs
revised after duplex-identified stenoses required
amputation. Graft revision for a duplex-identified
stenosis appears to confer a clear improvement in the
limb salvage and graft patency rates. In fact, the long-
term patency of grafts revised for stenosis does not
differ from the patency of grafts never requiring revi-
sion. This stands in stark contrast to the results for
revision of occluded grafts. Further analysis (Table V)
demonstrates that the mean cost of caring for patients
in whom graft thrombosis has occurred is significant-
ly higher than the cost of caring for patients under-
going elective graft revision (for 1 year, $45,252 vs
$17,688; P < .01). Obviously, the additional costs
generated in caring for patients with thrombosed
grafts resulted from a higher incidence of multiple
revisions and amputation and reflected the increased
cost associated with thrombolytic procedures.
Cost-benefit analysis. Although the preceding
analysis demonstrates superior patency and reduced
expense for grafts revised for duplex-identified
stenoses versus those revised after graft thrombosis,
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Table VI. Cost-benefit analysis of an intensive surveillance program versus revision for clinical indication
Intensive surveillance Clinically indicated 
(n = 150)* revision (n = 222)†‡
No. of grafts revised (%) 58 (37) 34 (13)
Revision before thrombosis 46 (29) 9 (4)
Revision after thrombosis 12 (8) 25 (9)
Cumulative graft patency (%)
1 y 91 84
5 y 82 67
Limb salvage (%)
1 y 96 83
5 y 92 73
Estimated cost per graft ($)
1 y 7,742 10,842
5 y 12,194 16,352
*Excluding early failures (< 30 days) from current series.
†Clinical patient data derived from Bergamini TM, et al. Ann Surg 1995;221:507-15.
‡It is assumed that 75% of all revisions are performed within 1 year of implantation and reminders are performed in following 4 years.
Cost estimation is based on 1998 cost data at the University of Arizona Health Science Center.
Estimated cost/patient = (% amputees)(cost amputation) + (% revision for stenosis)(cost revision for stenosis) + (% revision for throm-
bosis)(cost of revision for thrombosis) + cost of duplex examination (3 scans in first year, 9 scans in 5 years) [surveillance group only].
it remains less clear whether the surveillance pro-
gram prevents graft failure to a sufficient degree to
justify the expense incurred with multiple elective
revisions. This is a much broader question that can
be answered only through a cost-benefit analysis. In
this form of economic evaluation, attempts are made
to value the consequences of a given program in
monetary terms in such a way that one can compare
its benefit with that of another program.
Ideally, a prospective randomized trial could be
constructed to compare the cost benefit for patients
undergoing intensive surveillance versus patients
undergoing revision solely for clinical indicators of
graft failure (recurrent claudication, fall in ABI, loss
of a previously palpable pulse). The literature reports
two such series, only one of which was random-
ized.3,4 Both of these studies demonstrate a clear
benefit in terms of graft patency and limb salvage,
but neither addresses the potentially increased cost
associated with the surveillance program.
Recognizing the distinct benefits provided by a
surveillance program with respect to both graft
patency and limb salvage, we believe that it would be
unethical to deny surveillance to a subset of patients
solely for the purpose of determining the cost-
benefit ratio. Therefore, for the performance of
cost-benefit analysis of our graft surveillance pro-
gram, it is necessary to compare our results with
those for a historical group that had not undergone
intensive lower extremity duplex surveillance. For
the purposes of this analysis, we chose to use the
patient cohort reported by Bergamini et al3 in 1995.
The patients in this cohort, which is a contemporary
series, had preoperative demographics remarkably
similar to ours and were cared for in a similar uni-
versity hospital environment (see Appendix 2).
Significant differences between the two groups
include a lower incidence of claudication, a preferred
in situ bypass technique, and a higher incidence of
smoking and diabetes mellitus in Bergamini’s group.
Early failures (< 30 days) were excluded from this
analysis. Surgical revisions were performed only
when clinically indicated (recurrent symptoms, fall
in ABI, reduction in graft velocity, thrombosis).
Table VI compares the results from our series
with those of Bergamini et al.3 Theoretically, over 5
years an intensive surveillance program would have
required revision of duplex-identified stenoses in
29% of grafts, whereas the group undergoing revi-
sion for clinical indication required elective revision
in only 4% of grafts. The additional cost of these
procedures was offset by the improved limb salvage
rate (for 5 years, 92% vs 73%) and the avoidance of
costly amputation. The reduced cost and favorable
outcome in the intensive surveillance group support
its continued application.
DISCUSSION
Two features are inherent to any economic eval-
uation. First, such analysis involves consideration of
the costs and consequences of the intervention.
From the standpoint of the consumer, few people
would pay for a package—no matter how inexpen-
sive it might appear—without knowing its contents.
Likewise, few of us would accept a package—no
matter how desirable the contents—without know-
ing the specific price. It is the association between
cost and consequences that allows us to reach our
decision. Second, an economic analysis concerns
itself with choices. As the available medical resources
become fixed, our inability to provide all desired
outputs necessitates that choices be made on the
basis of program effectiveness. Economic analysis
establishes one basis on which the program may be
evaluated. As such, economic analysis is founded on
a comparative analysis of alternative courses of action
in terms of both the costs and the consequences.
Significant effort has been expended to better
characterize the incidence and time course of vein
graft stenoses. It is now clear that graft stenoses
develop soon after graft implantation, and the signif-
icance of this has been well described.6 Depending
on the criteria, thrombosis subsequently occurs in
23% to 65% of grafts in which stenoses are detected
but not repaired.10-15 Moreover, there is convincing
evidence that vein grafts that have thrombosed
before a surgical revision have significantly reduced
cumulative patency and are associated with an
increased amputation rate.16-22 The reasons for this
are multifactorial, but they almost certainly relate to
endothelial damage resulting from graft thrombosis.
Because of the relatively high frequency with
which infrainguinal vein grafts develop stenoses, the
high probability of graft failure in these stenotic
grafts, and the generally poor patency of graft revi-
sion when it is preceded by graft occlusion, it is not
surprising that surgeons have adopted protocols of
graft surveillance and elective graft revision. Since
Bandyk et al5 documented the potential applicability
of such programs, duplex surveillance has been wide-
ly adopted and graft patency and limb salvage rates
have improved by approximately 10% to 15%.11,14
However, the growing population of elderly
individuals and the fact that health care resources are
limited place a growing economic burden on the
health care industry and may force health care sys-
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tems to base future decisions on economics as well
as on efficacy. Analyses that demonstrate clinical effi-
cacy without consideration of associated costs can no
longer be accepted.
As the current study indicates, the expenses associ-
ated with graft surveillance are not negligible, and
claims that surgical revascularization is more cost effec-
tive than primary amputation must be revisited. This
study suggests that the mean cost of maintenance for
5 years approaches the cost of the primary operation.
Although the long-term cost of amputation remains
less clear, our study suggests that from the standpoint
of a pure cost analysis, primary amputation and limb
salvage approach equivalency. Although it is beyond
the scope of this report, the efficacy of each of the two
procedures can be measured only through use of a
cost-utility analysis, the first requirement of which is a
careful assessment of the preprocedural and postpro-
cedural quality of life. Our program has begun to gath-
er such data, and we look forward to presenting them
when they become available.
In the current study, 84% of patients undergoing
elective revision underwent preoperative contrast
angiography to confirm the significance of their
duplex-identified lesions and exclude more distal graft
lesions. Certainly, this contributes significantly to the
cost of the maintenance program. In an effort to min-
imize these costs, we no longer perform routine pre-
operative angiography. We are satisfied that duplex
scanning is of sufficient specificity to characterize a
hemodynamically significant lesion warranting repair.
We presently rule out a more distal graft lesion at the
time of surgical repair using either intraoperative com-
pletion angiography or duplex scanning.
Despite one’s best intentions to prevent graft
thrombosis, a small percentage of patients will pre-
sent with grafts that have failed. As this study indi-
cates, considerable resources are used in this patient
subgroup with suboptimal long-term outcome. In
this group, the merits of thrombolysis/revision can
be attributed only to technical ease. These proce-
dures are costly and result in high rates of failure
(40%-60% at 1 year) and subsequent amputation.
Indeed, the repeated application of graft thromboly-
sis or thrombectomy and revision remains dubious.
Redo bypass is likewise a costly endeavor and has the
added difficulty of being very labor intensive for the
surgeon, who must frequently splice together alter-
native conduits. The benefits of these procedures,
however, are an improved patency (80% at 1 year)
and durable limb salvage. Finally, the surgeon must
consider the consequences of continued observation
(low cost and low morbidity, but increased risk of
limb loss and impaired quality of life) or a definitive
major amputation (significant cost, impaired quality
of life). Accordingly, this group of patients deserves
careful consideration, and decisions must be individ-
ualized with regard to both the surgeon’s experience
and patient preference.
The real question of whether an intensive sur-
veillance program is more cost-effective than a pro-
gram in which revisions are performed for clinical
indications is a difficult one. To the best of our abil-
ity, we have attempted to perform an unbiased eco-
nomic appraisal of the maintenance of infrainguinal
bypass grafts. This analysis not only demonstrated
benefit in terms of patient outcome, measured as
graft patency and limb salvage; the patients under-
going intensive surveillance also generated fewer
expenses.
CONCLUSION
Novel technologies that provide incremental
patient benefit must be viewed with regard to their
financial consequences. Failure of health care
providers to do so is irresponsible in today’s era of
limited resources. In a world of fixed resources, the
real cost of a procedure relates not only to the
resources consumed but also to the inability to 
provide services for other, more cost-effective 
programs.
In assessing the quality of this study, one should
ask: How does this evaluation compare with our
usual basis for decision making? Like other authors,
we have demonstrated superior graft patency and
limb salvage through the application of an aggressive
graft surveillance program. However, it was neces-
sary to offer labor-intensive surveillance screening to
all patients and perform elective surgical revision in
nearly 30% of all grafts to obtain these satisfactory
rates of success. These activities generated significant
postimplantation expenses that were previously
unrecognized, and claims that limb salvage proce-
dures are cost-effective in comparison with amputa-
tion cannot be supported based solely on the present
cost analysis.
In comparison with a program in which revisions
are performed for clinical indications alone, an
intensive surveillance program appears to be effec-
tive in both reducing cost and improving graft
patency/limb salvage. Despite our best efforts, how-
ever, a small percentage of patients will present with
graft failure. This group represents a significant chal-
lenge to the vascular surgeon. On the basis of these
data, we are reluctant to recommend thrombolysis
and surgical revision. Rather, we have increased our
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willingness to observe these patients for recurrent
signs of ischemia. After graft thrombosis, we reserve
redo bypasses for otherwise functional patients in
whom limb-threatening ischemia recurs.
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APPENDIX 1. ESTIMATED COST OF
DUPLEX SURVEILLANCE EXAMINATION
This estimate is based on an 8-month analysis
(January-August 1998) of actual surveillance studies
performed at University Medical Center, Tucson, Ariz.
The following table presents information on the
numbers of studies:
No. of graft surveillance Total no. of nonin-
Month/year studies/mo vasive studies/mo
1/98 20 232
2/98 19 247
3/98 14 222
4/98 14 215
5/98 14 213
6/98 13 200
7/98 11 166
8/98 10 171
Totals 115 1666
Estimated number of surveillance studies per
year (based on 115 studies/8 mo): 175.
Estimated percent of laboratory time dedicated
to surveillance: 7.
The following table presents information on esti-
mated annual laboratory operating expenses (all fig-
ures are in US dollars):
Equipment
2 Advanced Technology 80,000
Laboratories (Bothell, Wash)
Maintenance 20,000
Personnel
Registered vascular technologist/ 102,000
registered nurse/clerical
Benefits 28,000
Facility/administrative fees 50,000
Total annual laboratory expenses 280,000
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Estimated annual expense of graft surveillance program: 
$19,600.
Estimated cost per study (based on projected 1998 data): 
$112.
Medicare reimbursement/study (CPT code 93926) 
$120.25.
APPENDIX 2. COMPARISON OF PATIENTS
UNDERGOING INTENSIVE SURVEIL-
LANCE AND PATIENTS UNDERGOING
REVISION FOR CLINICALLY INDICATED
PROCEDURES ONLY
The Table at right presents information on the
two patient groups.
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DISCUSSION
Dr P. Michael McCart (Santa Ana, Calif). Dr Wixon
and his colleagues analyzed the economic implications of
duplex ultrasound in the surveillance of infrainguinal vein
grafts. In their retrospective study, the mean 5-year cost of
graft maintenance approached that of the initial bypass.
Taken together, the limb salvage cost was equal to the cost
of primary amputation. Failed or thrombosed grafts
demonstrated very poor results with multiple revisions and
an amputation rate of 33%.
I agree with the cost-effect analysis but was impressed
with the $108,786 cost per limb saved. The data clearly
highlight the significant costs of thrombolysis and ampu-
tation. Because of this analysis, the authors did not rec-
ommend routine thrombolysis and surgical revision in the
failed graft.
I have some misgivings with the authors’ cost-benefit
analysis in that this study group was compared with a
1995 study at another institution. While the more aggres-
sive approach of the authors appeared favorable, there are
probably too many variables to clearly validate their con-
clusion. A more appropriate randomized trial was not
done for ethical reasons.
Despite the significant costs and retrospective nature
of the study, the data clearly show beneficial results. I have
three questions for the authors: (1) As most graft revisions
occurred in the first year, were completion angiography
and duplex scanning done at the original operation to
identify and allow repair of existing graft defects? (2) Have
you been able to identify a subset of patients with whom
you feel comfortable in reducing the number of postoper-
ative duplex examinations, both in the first year and long
term? (3) Have you considered anticoagulation with small
diameter grafts, low-flow states, or poor distal runoff?
In summary, I enjoyed this paper and feel the authors’
conclusions are appropriate. I also agree with the need to pro-
ceed with functional outcome analysis to better define when
alternative approaches to bypass should be considered. I look
forward to the Arizona group’s further work in this area.
Dr Christopher Wixon. Thank you, Dr McCart. With
regard to the first question regarding completion angiog-
raphy and intraoperative duplex scanning, completion
angiography is routinely performed at the conclusion of all
of our bypass procedures. In addition, if there is either clin-
ical suspicion or suspicion on the completion angiogram
that there is a hemodynamically significant lesion or
whether the vein was of questionable quality, then we selec-
tively use intraoperative duplex scanning.
The second question regards a subset of patients in
whom less frequent surveillance perhaps is warranted, and
I think that is probably true. Patients in whom no signifi-
cant flow abnormalities have been identified within the
first year were very unlikely to develop a hemodynamical-
ly significant stenosis in the future. Nonetheless, because
the majority of cost of a graft maintenance program is not
Clinically
Intensive indicated in-
surveillance* tervention†
(n = 150) (n = 222)
Patient demographics
Age (y) 69.1 ± 9.8 65 ± 17
Female gender (%) 43 37
Tobacco (%) 43 59 (P < .05)
Diabetes (%) 39 53 (P < .05)
Hypertension (%) 65 60
Indication
Critical ischemia (%) 79 92 (P < .05)
Graft origin
Femoral artery (%) 56 77 (P < .05)
Superficial femoral artery (%) 24 6
Profunda femoris artery (%) 8 1
Popliteal artery (%) 11 13
Graft insertion
Popliteal artery (%) 43 17 (P < .05)
Tibial/pedal artery (%) 56 83
Conduit
In situ (%) 19 76 (P < .05)
Reversed (%) 70 23
Other (%) 10.5 —
*Present data set, excluding early (<30 days) failures.
†Historical control group (Bergamini TM, et al. Ann Surg 1995,
221:507-15).
necessarily associated with the duplex examination but
more with the surgical revisions and the revisions of the
thrombosed grafts, we continue to survey these grafts at
6-month intervals.
In terms of chronic anticoagulation for perhaps poor
conduits, yes, that is a consideration, and it is left to the
surgeon’s discretion. Obviously if a graft had thrombosed
and it was lysed and a hemodynamically significant steno-
sis could not be uncovered, all of those patients were treat-
ed with chronic anticoagulation. The cost of chronic anti-
coagulation was not included in this study. I guess the
answer to your question is yes, it is done on a selective
basis.
Dr Wesley Moore (Los Angeles, Calif). I enjoyed this
paper very much, and I think the cost analysis has been
extremely well carried out.
With regard to your showing the equivalence of cost
between limb salvage and amputation, given that informa-
tion, I doubt that there would be very many patients that
would opt for amputation as opposed to salvage; rather,
they would use the fact that since it cost no more for sal-
vage, I would rather keep my leg, thank you.
My main reason for standing, however, is to just make
one comment with regard to that segment of your popu-
lation in which you have done femoral popliteal, not the
infrapopliteal reconstructions, and to put in a plug for
prosthetic reconstruction as an alternative to vein grafting.
One of the several advantages of PTFE is that you do
not need to carry out surveillance, and therefore, there
would be a cost savings. It is not that prosthetic grafts do
not thrombose. They certainly do, but you cannot predict
a prosthetic graft thrombosis on the basis of surveillance. 
When they do thrombose, however, the option of car-
rying out lytic therapy and returning them to a prethrom-
botic functional status is a lot better than it is for vein
grafts. I believe that you should reconsider the option of
prosthetic reconstruction when you have the popliteal
artery as a potential outflow site. Thank you.
Dr Wixon. Thank you, Dr Moore. I guess philosophi-
cally, our groups differ a little bit. I do agree that the sur-
veillance of femoropopliteal prosthetic grafts is probably
not warranted and there is no benefit in doing so.
However, the small cost savings in avoiding several sur-
veillance examinations is really small compared with the
additional costs of multiple thrombolytic procedures.
Thrombolysis in this series was really quite an expen-
sive endeavor. It required a lot of time in the intensive care
unit, expensive drugs, and one-on-one nursing care. I
have recently reviewed the complications associated with
catheter-based thrombolysis, and that procedure probably
carries a mortality of 1% to 2% and a major bleeding com-
plication of up to 20%.
So I do agree that if a prosthetic graft does thrombose
and the limb is threatened, then it is probably worthwhile
trying to resurrect it. However, I respectfully disagree
with the primary operation for patients with above-the-
knee popliteal segments.
Dr Ronald Dalman (Palo Alto, Calif). I very much
enjoyed your presentation. Economic cost analysis is an
important addition to our growing database regarding the
appropriate use of graft surveillance procedures.
Getting back to the similar point that Dr Moore
brought up, if I understood that correctly, you are com-
paring up-front costs of amputation with the 5-year cost
of limb salvage and subsequent maintenance procedures.
In our experience, up-front costs of amputation are just a
fraction of the total cost incurred in the first 5 years after
the procedure. Many patients (especially over the age of
70) require extensive rehabilitation, revised living arrange-
ments, prosthesis refittings and revisions. If they are ulti-
mately unable to use a prosthesis with any regularity, addi-
tional modifications to their home and transportation
infrastructure may be necessary.
This comparison is especially problematic today,
because underestimating the complete costs associated
with amputation may encourage third-party payers, HMO
units, etc, to devalue the relative benefit/cost ratio associ-
ated with graft surveillance and improved assisted primary
patency after limb salvage procedures.
A more accurate comparison would include a cohort
of amputees and calculate the total costs associated with
their care over a 5-year period. That distinction should be
addressed in both the presentation and the manuscript to
avoid confusion regarding the real “value” of graft sur-
veillance. Thank you.
Dr Mark Nehler (Denver, Colo). Did you make a mix-
ture? How did you come about the decision on what was
going to be the cost for amputation, and how many were
AKA or BKA?
Dr Wixon. The only patients who were included in the
amputation category were patients who were felt to be satis-
factory candidates to continue to ambulate. So if the patient
was going to be bed bound, the patient was excluded.
I did include both above-knee and below-knee ampu-
tations, but do not have the data as to what percentage
each one represented. The cost data for amputation did
reflect the cost of a temporary prosthesis, a permanent
prosthesis, and up to 30 days of rehabilitation. The addi-
tional costs of future amputation revisions and social
requirements are difficult costs to obtain and, therefore,
not included.
Dr Robert Rutherford (Silverthorne, Colo). I notice
that 19% of your cases had claudication, and there were
additional cases with aneurysms. In calculating your limb
salvage rate, did you include the cases that had claudica-
tion and project that into your cost analysis?
In other words, in terms of limb salvage, you were not
including the claudicants, were you?
Dr Wixon. That is correct.
Dr Ralph DePalma (Reno, Nev). Well, I enjoyed the
paper; it brings to mind something that we did almost 20
years ago. I took all the index operations, aorta, fem-pop,
and carotid from the Cleveland Vascular Registry to Dr
Herbert Mosteller, who was then head of the AAAS and a
mathematician at Harvard concerned with health care
matters. We looked at cost-benefit ratios for our work
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because I was sure that doing vascular surgery in general
was cost-effective and a very good thing to do. After 6
months Dr Mosteller, a very honest man, came back and
he was very upset, very sad. He said to me, “Ralph, the
better you guys get, the more it costs.”
My question derives around whether cost-benefit
ratios, and I have looked into them quite a bit, are some-
thing at all applicable to human beings but rather govern-
ment estimates for bridges and highways. There is a dis-
count rate in the cost ratio. More important, an age factor
occurs in the denominator so that the shorter the durabil-
ity of the procedure or the life of the patient, the more
costly or ineffective it appears. I wonder where we are
going to go with this. The better we get, the more it costs.
It clearly is cheaper not to treat at all—from a “cost-ben-
efit” point of view for a vascular disease population.
I would like to ask you to take a look at the cost-ben-
efit ratio and look at the classic way in which it is applied
to government projects such as bridges and highways. See
if you can factor in, perhaps a human factor into the
denominator or amplify the numerator appropriately.
Dr Wixon. I think you are right. Cost benefit, by look-
ing only at the limb salvage or graft patency rate, is gross-
ly inadequate. What we need to be doing is cost utility
analysis, which accounts for the patient’s quality of life. I
think there are patients in whom bypasses are performed
who do not benefit from them. They keep their leg, but
their quality of life is not improved.
We have recently begun to measure quality of life on
all patients with lower extremity ischemia: patients under-
going primary amputations, patients treated conservative-
ly for claudication, and patients in whom bypasses have
been constructed. We look forward to presenting those
data in the future.
Dr DePalma. Well, I beg you not to put a price on it.
Dr Peter Lawrence (Irvine, Calif). This morning we
have heard several different approaches to graft surveil-
lance, with respect to frequency and criteria for repair. I
wonder if you have done a closer analysis of your data to
provide cost/benefit data.
Have you looked at breaking it down into the standard
approaches that different institutions use to determine
whether there’s an optimal method of graft surveillance?
Dr Wixon. I think that is a good point. I think the fre-
quency or interval with which we perform surveillance is
less important. During the first year, I believe most insti-
tutions perform some variant of every 3-month surveil-
lance and then go to every 6 months after that. I think
that is correct as the highest incidence of graft stenosis
occurs within the first year of bypass.
I think the real difference that we need to examine is
the criteria by which institutions determine a graft to be a
risk. We have tried to increase the specificity of our crite-
ria by using higher velocity ratios (3.5) and peak systolic
velocities (300 cm/s). I think the Oregon group reported
that peak systolic velocities of 200 cm/s were used to
identify grafts at risk.
For these intermediate lesions (200 cm/s < PSV < 300
cm/s), we continue to survey them with increased inten-
sity (every 3 months). We do not subject those patients to
costly arteriograms or surgical revision. We have not
observed failure in any grafts with intermediate criteria.
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